Aurora Cannabis vs Curaleaf – hostile bid outcome

As of September 3, 2026, the primary baseline event is Curaleaf Holdings' (TSX: CURA) unsolicited hostile takeover bid for Aurora Cannabis Inc. (TSX: ACB). On September 2, 2026, Aurora’s Board of Directors formally rejected the bid, urging shareholders to disregard the offer, claiming it undervalues the company and its future upside [2]. Curaleaf has countered, reaffirming its offer—which reportedly includes a 45% premium—as the superior path for shareholder value creation [3]. This conflict follows Aurora's August 10, 2026, Annual General Meeting (AGM), where shareholders confirmed the current leadership, including CEO Miguel Martin (85.12% approval) and Chairman Michael Singer (86.34% approval) [1]. While Curaleaf continues retail expansion with new dispensary openings in Boston and Florida [2][3], the regulatory focus remains on the TSX-listed entities' competing circulars and the potential for further hostile maneuvers or white knight interventions.

As of September 3, 2026, both Aurora Cannabis (ACB) and Curaleaf Holdings (CURLF) are current with their multi-jurisdictional filing requirements. Aurora has released approximately 60 regulatory filings year-to-date in 2026, including its 10-K annual report and subsequent quarterly disclosures [1][2]. Curaleaf continues to report under both SEC and CSA guidelines, with its most recent major MD&A filed in February 2026 [11] and operational updates confirming a footprint of 164 dispensaries across 15 states as of Q1 2026 [7]. Both entities utilize SEDAR+ for Canadian disclosures and EDGAR for U.S. filings [4][10]. The baseline for this watch is established following the September 2, 2026, updates to their SEC filing histories [1][6]. Open threads include the upcoming Q3 2026 financial results and any ad-hoc TSX/NASDAQ announcements regarding shareholder meetings or material corporate changes.